Introduction {#S0001}
============

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide.^[1](#CIT0001),[2](#CIT0002)^ Lung adenocarcinoma is the most common sub-type of NSCLC.^[3](#CIT0003)^ An increasing number of driver gene alterations have been identified in NSCLC, most notably associated with epidermal growth factor receptor (*EGFR*), chromosomal rearrangements involving the anaplastic lymphoma kinase gene (*ALK*), and the c-ros oncogene 1 (*ROS1*). *ROS1* encodes for an orphan receptor tyrosine kinase from the insulin receptor family that is related to *ALK*.^[4](#CIT0004)^ Between 1% and 2% of patients with NSCLC harbor a *ROS1* rearrangement and the incidence is slightly higher in the East Asian population (2%-3%).^[5](#CIT0005),[6](#CIT0006)^ Currently, a total of 16 *ROS1* fusion partner genes have been reported in NSCLC, including *CD74, SLC34A2, GOPC, CCDC6, SDC4, TPM3, EZR, LRIG3, KDELR2, LIMA1, MSN, CLTC, TPD52L1, FIG, TMEM106B, FAM135B, SLC6A17*, and *CEP72*.^[7](#CIT0007)--[10](#CIT0010)^ In addition, MET is also a potential therapeutic target in NSCLC and *MET* amplification has a frequency of 5%-20%.^[11](#CIT0011)^ Both *ROS1* gene rearrangements and de novo *MET* amplification have been described as rare oncogenic events in *EGFR* gene-negative NSCLC patients.

Crizotinib is a first-generation, small-molecule tyrosine kinase inhibitor (TKI) originally designed to target MET that has been shown to be effective against lung cancers harboring *ALK* or *ROS1* alterations.^[12](#CIT0012),[13](#CIT0013)^ Based on a phase I trial, crizotinib was shown to have an objective response rate (ORR) of 72% and a median progression-free survival (PFS) of 19.2 months in advanced *ROS1*-rearranged NSCLC.^[14](#CIT0014)^ While, some cases have shown a good response to crizotinib,^[15](#CIT0015)^ the efficacy of crizotinib for NSCLC patients with de-novo *MET* amplifications NSCLC has not been determined in a large clinical study.

Therefore, an accurate diagnosis is important with respect to the treatment and prognosis of NSCLC patients. Developing a multi-molecular test is a key step in identifying genetic alterations. The significance of the next generation sequencing (NGS) assay for molecular diagnoses in NSCLC patients is of increasing importance and has become common in clinical practice.^[2](#CIT0002)^

No study has reported NSCLC with a co-existing *ZCCHC8-ROS1* rearrangement and MET gene amplification and the efficacy of treatment with crizotinib.

Clinical case report {#S0002}
====================

In May 2016, a 65-year-old Chinese female, a non-smoker, presented to our hospital for a physical examination that revealed pulmonary nodules. A computed tomography (CT) scan showed a mass in the right middle lung. A brain-enhanced MRI and an abdominal CT were not revealing. Then, she underwent surgery and a post-operative pathologic examination showed a peripherally invasive right lung adenocarcinoma (1.5 cm) and pleural nodule metastases. Immunohistochemical staining was positive for TTF-1 and Napsin A, and negative for CK5/6 and P40. According to the 7^th^ edition of TNM staging, the patient was classified as stage IVA (T~1~N~0~M~1a~). Examination of the tumor tissue revealed wild-type epidermal growth factor receptor (*EGFR*) variants by ARMS (AmoyDx, Xiamen, China), and ALK protein expression was detected with the Ventana ALK IHC assay (Ventana Medical Systems, Roche, Inc., Tucson, AZ, USA). She consented to post-operative chemotherapy with two cycles of chemotherapy (docetaxel, 75 mg/m^2^ day 1 and cisplatin, 25 mg/m^2^ days 1--3 \[DP\]). Because of a venous thrombosis, chemotherapy was delayed and the disease had progressed in September 2016. There were multiple brain metastases, thus she received whole brain radiotherapy (WBRT; 30 Gy in 10 fractions). At the same time, the specimen was subjected to NGS and both *ZCCHC8-ROS1* fusion ([**Figure 1**](#F0001)) and de-novo *MET* gene amplification ([**Figure 2A**](#F0002)) were detected. De-novo *MET* amplification was confirmed using a MET/CEN7q Dual Color FISH Probe (Vysis; Abbott Molecular, Des Plaines, IL, USA) ([**Figure 2B**](#F0002)). The results showed *MET* amplification. Because of progression of lung lesions, the patient began crizotinib therapy in November 2016 ([**Figure 3A**](#F0003)**, C)**. After 1 month, assessment with computed tomography and brain MRI scans revealed a partial response, according to the Response Evaluation Criteria 1.1 in Solid Tumors ([**Figure 3B**](#F0003)**, D)**. During crizotinib therapy, she had first-degree liver dysfunction and gastrointestinal side effects. There were no other treatment-related adverse events, including rashes, renal function, and cordis damage. Unfortunately, after 6 months, the disease progressed. Then, she received nedaplatin and apatinib and the overall survival was 22 months.10.1080/15384047.2018.1491506-F0001Figure 1.*ZCCHC8-ROS1* fusion is clinically actionable. A, the integrative genomics viewer snapshot of *ZCCHC8-ROS1*. soft-clipped bases can match each other in reverse complementarity. B, schematic representation of the *ZCCHC8-ROS1* fusion protein domain structure. Blue, *ZCCHC8*; red, *ROS1; ZCCHC8-ROS1*. Fusion protein is 502 amino acids in length.10.1080/15384047.2018.1491506-F0002Figure 2.*MET* amplication show (A) NGS (CNV from 2 to 8) and (B) FISH (MET/CEN7 ratio = 2.26).10.1080/15384047.2018.1491506-F0003Figure 3.Computed tomography (CT) scans show: A, before crizotinib therapy; B, CT of the chest showed partial response after months of crizotinib. brain MRI show: C, before crizotinib therapy; D, MRI of the brain showed partial response after months of crizotinib.

Discussion {#S0003}
==========

This is the first report of a co-existing *ROS1* fusion and de-novo *MET* amplification in a patient with NSCLC. In addition, a new fusion type of *ROS1* (*ZCCHC8*) was identified and the effect of EGFR-TKI in an NSCLC patient is reported. Considering this rare type of *EGFR* mutation and having a good response to TKI therapy, we recommend that clinicians should realize the existence of co-existing gene mutations in NSCLC patients.

Initially, driver gene mutations in NSCLC, such as *EGFR, KRAS, HER2, BRAF, ALK, RET, ROS1*, and *MET*, were regarded as independent, mutually exclusive events.^[16](#CIT0016)^ In recent years, more and more cases of lung cancer with co-existing alterations of *EGFR, ALK, ROS1*, and *KRAS* have been reported.^[17](#CIT0017)--[19](#CIT0019)^ Co-existing *EGFR* or *KRAS* mutations and *ROS1* fusion were the most common associations. Warth et al.^[20](#CIT0020)^ reported *ROS1* translocations occurring in conjunction with other driver mutations (*EGFR, KRAS*, and *BRAF*). In addition, Wiesweg et al.^[21](#CIT0021)^ showed that ROS1-IHC-positive patients presented with co-existing oncogenic driver mutations, such as *EGFR* (six cases), *KRAS* (two cases), *PIK3CA*, and *BRAF*. To date, only two patients harboring *ROS1* and *ALK* concomitant rearrangements have been reported in the literature. Song et al.^[22](#CIT0022)^ and Zhu et al.^[18](#CIT0018)^ each reported one patient with a co-existing *ALK*/*ROS1* rearrangement. Indeed, very few co-existing genes have been reported with *MET* gene amplification. Wang et al.^[23](#CIT0023)^ reported a patient with a *KLC1-ALK* fusion and *MET* gene amplification-positive NSCLC. Therefore, a concomitant *ROS1* gene rearrangement and *MET* amplification is rare. Tang and colleagues^[19](#CIT0019)^ explored co-existing genetic alterations involving *ALK, RET, ROS1*, or *MET* in 15 patients with lung adenocarcinomas, and found a case of *ROS1* combined with *MET*; however, Tang et al.^[19](#CIT0019)^ did not show a specific fusion type and had no crizotinib treatment.

In addition, *ZCCHC8-ROS1* fusion was first discovered in NSCLC. *ZCCHC8*, as a fusion partner of *ROS1*, was first demonstrated in a case of congenital glioblastoma multiforme with a t (6; 12) (q21;q24.3).^[24](#CIT0024)^ Therefore, the efficacy of inhibitors, such as crizotinib, for this type of *ROS1* fusion was unknown.

Crizotinib, as an ALK/ROS1/MET inhibitor, is associated with an ORR of 72% and a median PFS of 19.2 months in advanced *ROS1*-rearranged NSCLC.^[14](#CIT0014)^ Recently, a phase II study involving crizotinib in East Asian patients with *ROS1*-positive advanced NSCLC (127 patients) resulted in an ORR of 71.7% and a median PFS of 15.9 months.^[25](#CIT0025)^ In contrast, NSCLC patients with a *de novo MET* amplification represents an uncommon sub-type of gene alteration in lung cancer. Although preliminary data from case reports has demonstrated promising efficacy of crizotinib treatment in NSCLC patients with de novo *MET* amplifications,^[26](#CIT0026),[27](#CIT0027)^ studies involving a large number of patients with NSCLC and de novo *MET* amplifications are lacking. Therefore, crizotinib provides meaningful clinical benefit in patients with *ROS1*-positive or *MET* amplification advanced NSCLC. Wang et al.^[23](#CIT0023)^ showed a rapid response to crizotinib in a patient with brain metastases and a *KLC1-ALK* fusion and de-novo *MET* gene amplification; however, the patient did not continue crizotinib and did not achieve a PFS. Although, our patients also showed a good response to crizotinib therapy, the PFS was only 6 months. We conclude that NSCLC patients with co-existing driver gene alterations have a good response to crizotinib, but disease control time may be different from single gene mutation. Additional clinical data to verify the efficacy of crizotinib treatment in patients with advanced NSCLC and *ROS1* fusion and de-novo *MET* amplification is warranted.

We should be aware of the phenomenon of concomitant *ROS1* and de-novo *MET* amplification. There is currently no standard therapy for patients with co-existing driver genes. If concurrent driver fusions are identified, targeted therapy with the guidance of precise diagnosis should be offered; however, co-existing driver fusions may have potential clinical implications as biomarkers for a relatively poor prognosis.
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[^1]: Color versions of one or more of the figures in the article can be found online at [www.tandfonline.com/kcbt](http://www.tandfonline.com/KCBT).
